Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03289910 · OUTCOME

Number of Participants With Minimal Residual Disease (MRD) After Treatment

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia · Source last updated 2026-06-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
Up to 7 months

What was measured

Minimal residual disease (MRD) refers to a small number of leukemic cells that remain after treatment.

Analysis population: Data was not collected.

Groups in this outcome

Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin)

Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

Arm B (Topotecan Hydrochloride, Carboplatin)

Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin)0
Arm B (Topotecan Hydrochloride, Carboplatin)0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    2. group Id
      OG001
      value
      0
    units
    Participants
description
Minimal residual disease (MRD) refers to a small number of leukemic cells that remain after treatment.
groups
  1. description
    Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin)
  2. description
    Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.
    id
    OG001
    title
    Arm B (Topotecan Hydrochloride, Carboplatin)
population Description
Data was not collected.
reporting Status
POSTED
time Frame
Up to 7 months
title
Number of Participants With Minimal Residual Disease (MRD) After Treatment
type
SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice